Literature DB >> 8903367

Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology.

S Zeuzem1, A Franke, J H Lee, G Herrmann, B Ruster, W K Roth.   

Abstract

Nucleotide sequence analysis of hepatitis C virus (HCV) strains showed substantial variability leading to a classification into several genotypes and subtypes. The data correlating HCV genotypes and subtypes with hepatitis C viremia levels, demographic characteristics of patients (age, mode of transmission, duration of infection), and severity of liver disease are conflicting. The interpretation of several studies is further complicated because the molecular methods used lacked specificity for genotyping/subtyping and underestimated viremia levels, especially in patients infected with HCV genotypes 2 and 3. In the present study we investigated 97 consecutive patients with chronic hepatitis C using molecular "gold standard" methods. HCV subtyping was performed by sequence and phylogenetic analysis of the nonstructural (NS)-5 region and serum HCV-RNA concentration was assessed by a validated genotype-independent quantitative reverse-transcription-polymerase chain reaction assay using an internal RNA standard. Patients infected with subtypes HCV-1b, HCV-2a-c, and HCV-4 were older than patients infected with HCV-1a and HCV-3a. Serum HCV-RNA levels ranged from 1.5 x 10(4) to 1.0 x 10(8) copies/mL with no significant differences between median serum HCV-RNA concentrations in patients infected with different genotypes/subtypes. Although patients infected with HCV-1b were older, no biochemical or histological evidence was obtained that this subtype is associated with more severe liver disease. Furthermore, the present study showed a lack of correlation between the serum HCV-RNA concentration, biochemical parameters, and liver histology. The median serum HCV-RNA levels in patients with chronic persistent hepatitis, chronic active hepatitis, and liver cirrhosis were 5.0 x 10(6) copies/mL, 2.5 x 10(6) copies/mL, and 5.0 x 10(6) copies/mL, respectively. These differences were not significant. In conclusion, using optimized and validated molecular techniques, the present cross-sectional study showed no correlation between HCV genotypes/subtypes, viremia, liver function test results, and histology.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8903367     DOI: 10.1002/hep.510240505

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  20 in total

1.  Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology.

Authors:  J Devlin; J O'Grady
Journal:  Gut       Date:  1999-12       Impact factor: 23.059

Review 2.  Quantitative molecular analysis of virus expression and replication.

Authors:  M Clementi
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

3.  Impact of smoking on histological liver lesions in chronic hepatitis C.

Authors:  C Hézode; I Lonjon; F Roudot-Thoraval; J-P Mavier; J-M Pawlotsky; E S Zafrani; D Dhumeaux
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

4.  Influence of iron on the severity of hepatic fibrosis in patients with chronic hepatitis C.

Authors:  Tsung-Jung Lin; Li-Ying Liao; Shyr-Yi Lin; Chih-Lin Lin; Ting-An Chang
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

5.  Genetic clustering of hepatitis C virus strains and severity of recurrent hepatitis after liver transplantation.

Authors:  M Gigou; A M Roque-Afonso; B Falissard; F Penin; E Dussaix; C Féray
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

6.  Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C.

Authors:  L E Adinolfi; R Utili; A Andreana; M F Tripodi; M Marracino; M Gambardella; M Giordano; G Ruggiero
Journal:  Dig Dis Sci       Date:  2001-08       Impact factor: 3.199

7.  Plasma hydroxy metronidazole/metronidazole ratio in anti-HCV carriers with and without apparent liver disease.

Authors:  C M da Silva; F L David; M N Muscará; S S Sousa; J G Ferraz; G de Nucci; N C Polimeno; J Pedrazzoli
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

8.  Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat.

Authors:  Liliana Gazzuola Rocca; Barbara P Yawn; Peter Wollan; W Ray Kim
Journal:  Ann Fam Med       Date:  2004 Mar-Apr       Impact factor: 5.166

9.  Assessment of correlation between serum titers of hepatitis C virus and severity of liver disease.

Authors:  Bhupinder-S Anand; Maria Velez
Journal:  World J Gastroenterol       Date:  2004-08-15       Impact factor: 5.742

10.  Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study.

Authors:  Vincent Lo Re; Michael J Kallan; Janet P Tate; A Russell Localio; Joseph K Lim; Matthew Bidwell Goetz; Marina B Klein; David Rimland; Maria C Rodriguez-Barradas; Adeel A Butt; Cynthia L Gibert; Sheldon T Brown; Lesley Park; Robert Dubrow; K Rajender Reddy; Jay R Kostman; Brian L Strom; Amy C Justice
Journal:  Ann Intern Med       Date:  2014-03-18       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.